Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class ...
Proprietary T-Bolt™ technology dramaticallybroadens the benefits of immunotherapy by targeting the entire universe of cancer antigens
Source: eagletribune.com